Efficacy of Hi-tACS for Schizophrenia Negative Symptoms
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The goal of this clinical trial is to investigate whether Hi-tACS is effective and safe in treating negative symptoms of schizophrenia. Schizophrenic patients will receive treatment (Hi-tACS or shame stimulation) for 2 weeks. Negative symptoms, cognitive functioning, social functioning, and quality of life of intervention group and control group were assessed and compared between the two groups at baseline, 2 weeks, and 3 months post-intervention.
Eligibility Criteria
Inclusion Criteria: * Han Chinese population; * Age ≥ 18 years; * Education level ≥ 6 years, able to fill out questionnaires on their own, and having sufficient audiovisual level to complete the necessary examinations; * Meets DSM-5 diagnostic criteria for schizophrenia as assessed by MINI 7.0; * Residual negative symptoms, with at least one item ≥2 on the negative subscale of PANSS (N1-N7); * Taking second-generation atypical antipsychotic medication, with no medication or dosage adjustments in the last two weeks * Patients and guardians agreed to participate in the study and signed an informed consent form. Exclusion Criteria: * Meets DSM-5 diagnostic criteria for other mental disorders; * Total score ≥19 on the PANSS positive subscales (P1-P7) ; * Severe negative symptoms that prevent the patient from completing the required assessments and interventions; * Serious physical or central nervous system disease (intracranial infection, intracranial tumor, presence of metal objects in th